https://scholar.google.com/citations?user=UObFbYUAAAAJ&hl=en&oi=ao

•Pradhan T, Sarkar R, Meighen-Berger KM, Feige MJ, Zacharias M, Reif B.
Mechanistic insights into the aggregation pathway of the patient-derived immunoglobulin light
chain variable domain protein FOR005. Nat Commun. 2023 Jun 23;14(1):3755.

• Blahut J, Brandl MJ, Pradhan T, Reif B, Tošner Z. Sensitivity-Enhanced Multidimensional
Solid-State NMR Spectroscopy by Optimal-Control-Based Transverse Mixing Sequences.
J Am Chem Soc. 2022 Sep 28;144(38):17336-17340.

• Pradhan T, Annamalai K, Sarkar R, Huhn S, Hegenbart U, Schönland S, Fändrich M,
Reif B. Solid state NMR assignments of a human λ-III immunoglobulin light chain amyloid fibril.
Biomol NMR Assign. 2021 Apr;15(1):9-16

• Schönfelder J, Pfeiffer PB, Pradhan T, Bijzet J, Hazenberg BPC, Schönland SO,
Hegenbart U, Reif B, Haupt C, Fändrich M. Protease resistance of ex vivo amyloid
fibrils implies the proteolytic selection of disease-associated fibril morphologies.
Amyloid. 2021 Dec;28(4):243-251.

• Pradhan T, Annamalai K, Sarkar R, Huhn S, Hegenbart U, Schönland S, Fändrich M,
Reif B. Seeded fibrils of the germline variant of human λ-III immunoglobulin light chain
FOR005 have a similar core as patient fibrils with reduced stability. J Biol Chem. 2020
Dec 25;295(52):18474-18484.

• Weber B, Hora M, Kazman P, Pradhan T, Rührnößl F, Reif B, Buchner J.
Domain Interactions Determine the Amyloidogenicity of Antibody Light Chain Mutants.
J Mol Biol. 2020 Nov 20;432(23):6187-6199.

• Weber B, Brandl MJ, Pulido Cendales MD, Berner C, Pradhan T, Feind GM, Zacharias M,
Reif B, Buchner J. A single residue switch reveals principles of antibody domain integrity.
J Biol Chem. 2018 Nov 2;293(44):17107-17118.

• Singh SP, Wahajuddin, Tewari D, Pradhan T, Jain GK.
PAMPA permeability, plasma protein binding, blood partition, pharmacokinetics and metabolism
of formononetin, a methoxylated isoflavone. Food Chem Toxicol. 2011 May;49(5):1056-62.

• SP Singh, K Patel, T Pradhan, HH Siddiqui, SK Singh
Prediction of human absorption of a trioxane antimalarial drug (CDRI 99/411) using an in-house
validated in situ single-pass intestinal perfusion model
Arzneimittelforschung 61 (09), 532-537,2011